Jul 29, 2024
Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis
Mar 28, 2024
Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade
Mar 26, 2024
Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology
Sep 22, 2020
Bridge Biotherapeutics Announces Detailed Plans for the Phase 2a Study of BBT-401
Jul 14, 2020
Bridge Biotherapeutics becomes BaseLaunch's first Asia Pacific partner
May 07, 2020
Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea
Apr 09, 2020
Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis
Feb 05, 2020
Bridge Biotherapeutics Acquires a New Drug Development Candidate for Back-Eye Diseases
Jan 19, 2020
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC
Dec 26, 2019
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC
Dec 19, 2019
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC
Jul 02, 2019
Bridge Biotherapeutics Joins JLABS @ Shanghai, China
May 19, 2019
Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis
Feb 11, 2019
Bridge Biotherapeutics Presented Preclinical and Phase I Study Results for BBT-401 at the Crohn's & Colitis Congress
Jan 16, 2019
Bridge Biotherapeutics Announces FDA Orphan Drug Designation for BBT-877 in Idiopathic Pulmonary Fibrosis (IPF)
Dec 27, 2018
Bridge Biotherapeutics Announces a Successful Activation of U.S. Clinical Trial Sites for BBT-401 Phase 2 Study
Dec 18, 2018
Bridge Biotherapeutics Signs US$40M License Agreement with Daewoong Pharmaceutical for Co-development of UC Drug Candidate
Dec 16, 2018
Bridge Biotherapeutics Announces FDA Clearance of IND for its BBT-877, an Autotaxin Inhibitor for IPF
Nov 18, 2018
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-877, an Autotaxin Inhibitor for Idiopathic Pulmonary Fibrosis
Nov 12, 2018
The First Pellino-1 Inhibitor BBT-401 Confirms Its Safety and Tolerability from the Phase I Study